In this issue, Sung and colleagues attempt to address an important clinical quandary: In patients who develop peptic ulcer
bleeding while receiving antiplatelet therapy, should antiplatelet therapy be stopped, and, if so, for how long? Their findings
force us to reconsider the focus on the gut in upper gastrointestinal bleeding and remind us to consider the patient as a
whole.